Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Elimination of FVIII-Specific B Cells By Immunotoxins Comprised of a Single FVIII Domain Fused to Pseudomonas Exotoxin a

Kerstin Brettschneider, Anja Schmidt, PhD, Joerg Kahle, PhD, Aleksander Orlowski, Diana Stichel, Karin Becker-Peters, Sonja Neimanis, PhD, Christine Heller, MD, Thomas Klingebiel, MD, Dirk Schwabe, MD, Christoph Koenigs, MD PhD

Blood (2016) 128 (22): 561.

https://doi.org/10.1182/blood.V128.22.561.561

Published: 2016

Journal Articles

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Michael Pfreundschuh, MD, Lorenz Thurner, MD, Stefan Barth, Prof.Dr., Diana Pickert, Natalie Fadle, Maria Kemele, Evi Regitz, Frank Neumann, PhD, Thomas Nachreiner, Dr., Klaus-Dieter Preuss, PhD

Blood (2015) 126 (23): 3995.

https://doi.org/10.1182/blood.V126.23.3995.3995

Published: 2015

Journal Articles

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

Fabian Mueller, MD PhD, Xiu-Fen Liu, PhD, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2015) 126 (23): 1332.

https://doi.org/10.1182/blood.V126.23.1332.1332

Published: 2015

Journal Articles

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Robert J. Kreitman, MD, Evgeny Arons, PhD, Martin S Tallman, MD, Robak Tadeusz, MD PhD, Steven Coutre, MD, Wyndham H Wilson, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Lanasa, MD PhD, David JP FitzGerald, PhD, Ira Pastan, MD

Blood (2015) 126 (23): 4161.

https://doi.org/10.1182/blood.V126.23.4161.4161

Published: 2015

Journal Articles

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

Lina Han, PhD, Eric Rowinsky, MD, Christopher Brooks, PhD, Tomasz Zal, M. Anna Zal, Jared K Burks, PhD, Jin Zhou, MD PhD, Stefan O. Ciurea, MD, Gheath Alatrash, Jorge E. Cortes, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Farhad Ravandi, MD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 981.

https://doi.org/10.1182/blood.V124.21.981.981

Published: 2014

Journal Articles

Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Trishna Goswami, MD, Fujun Wang, PhD, Ramy Ibrahim, MD

Blood (2013) 122 (21): 5021.

https://doi.org/10.1182/blood.V122.21.5021.5021

Published: 2013

Journal Articles

Variability In Precursor B ALL Killing With Moxetumomab Pasudotox (CAT-8015) Linked To Differential Binding and Endocytic Trafficking

Ksenia Matlawska-Wasowska, PhD, Christian K. Nickl, Stuart S. Winter, MD, Patricia Burke, Theresa LaVallee, PhD, Bridget S. Wilson, PhD

Blood (2013) 122 (21): 5022.

https://doi.org/10.1182/blood.V122.21.5022.5022

Published: 2013

Journal Articles

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Robert J. Kreitman, MD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H Wilson, MD, PhD, David J. P. FitzGerald, PhD, Ira Pastan, MD

Blood (2013) 122 (21): 2871.

https://doi.org/10.1182/blood.V122.21.2871.2871

Published: 2013

Journal Articles

RhoA Is Essential for Maintaining Normal Megakaryocyte Ploidy Distribution and Platelet Generation

Aae Suzuki, Jae-Won Shin, Ph.D., Yuhuan Wang, PhD, Mortimer Poncz, MD, John K. Choi, MD, PhD, Dennis E Discher, Ph.D., Christopher L. Carpenter, MD, PhD, Lurong Lian, Liang Zhao, Ph.D., Yanfeng Wang, Charles S. Abrams, MD

Blood (2012) 120 (21): 385.

https://doi.org/10.1182/blood.V120.21.385.385

Published: 2012

Journal Articles

The CD317-Targeted Immunotoxin HM1.24-ETA′ Efficiently Eliminates Malignant Plasma Cells in Vitro and in Vivo

Matthias Staudinger, Pia Glorius, Christian Kellner, Andreas Guenther, Roland Repp, Renate Burger, Martin Gramatzki, Matthias Peipp

Blood (2012) 120 (21): 1838.

https://doi.org/10.1182/blood.V120.21.1838.1838

Published: 2012

Journal Articles

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

Robert J. Kreitman, MD, Evgeny Arons, PhD, Sapolsky Jeffrey, Laura Roth, Hong Zhou, BS, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H. Wilson, MD, PhD, Mark Raffeld, MD, David J. P. FitzGerald, PhD, Ji Fei, PhD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2012) 120 (21): 2896.

https://doi.org/10.1182/blood.V120.21.2896.2896

Published: 2012

Journal Articles

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma.

Christopher L. Brooks, PhD, Thomas P. Cirrito, PhD, Kenneth Hoberman, Eric Rowinsky, MD

Blood (2012) 120 (21): 2768.

https://doi.org/10.1182/blood.V120.21.2768.2768

Published: 2012

Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2011) 118 (21): 248.

https://doi.org/10.1182/blood.V118.21.248.248

Published: 2011

Journal Articles

Mycobacterium Tuberculosis infection and Tissue Factor Expression in Macrophages

Hema Kothari, Ph.D., Ramakrishna Vankayalapati, Ph.D., Padmaja Paidipally, L. Vijaya Mohan Rao, Ph.D., Usha R Pendurthi, Ph.D.

Blood (2011) 118 (21): 1198.

https://doi.org/10.1182/blood.V118.21.1198.1198

Published: 2011

Journal Articles

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Rimas J Orentas, PhD, Waleed Haso, B.S., Richard A. Morgan, Ira Pastan, MD, Crystal L Mackall, MD

Blood (2011) 118 (21): 4313.

https://doi.org/10.1182/blood.V118.21.4313.4313

Published: 2011

Journal Articles

Mice That Lack RhoA In Their Platelets Have Normal Actin Dynamics, but Have Macrothrombocytopenia

Aae Suzuki, Lurong Lian, Liang Zhao, Sang H. Min, MD, Yuhuan Wang, Mortimer Poncz, MD, John K Choi, Christopher L. Carpenter, MD, PhD, Charles S. Abrams, MD

Blood (2010) 116 (21): 549.

https://doi.org/10.1182/blood.V116.21.549.549

Published: 2010

Journal Articles

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Robert J. Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H. Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 2516.

https://doi.org/10.1182/blood.V116.21.2516.2516

Published: 2010

Journal Articles

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Robert J Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert Lechleider, MD, Karen Kaucic, MD, Ira Pastan, MD

Blood (2009) 114 (22): 888.

https://doi.org/10.1182/blood.V114.22.888.888

Published: 2009

Journal Articles

Bryostatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy.

Ingo Ringshausen, Thomas Decker, Viola Biberacher, Christian Meyer zum Buschenfelde, Madlen Oelsner, Michaela Wagner, Christian Bogner, Christian Peschel, MD

Blood (2009) 114 (22): 3429.

https://doi.org/10.1182/blood.V114.22.3429.3429

Published: 2009

Journal Articles

Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.

Robert J Kreitman, MD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Ira Pastan, MD

Blood (2009) 114 (22): 3442.

https://doi.org/10.1182/blood.V114.22.3442.3442

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Elimination of FVIII-Specific B Cells By Immunotoxins Comprised of a Single FVIII Domain Fused to Pseudomonas Exotoxin a

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL)

Variability In Precursor B ALL Killing With Moxetumomab Pasudotox (CAT-8015) Linked To Differential Binding and Endocytic Trafficking

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

RhoA Is Essential for Maintaining Normal Megakaryocyte Ploidy Distribution and Platelet Generation

The CD317-Targeted Immunotoxin HM1.24-ETA′ Efficiently Eliminates Malignant Plasma Cells in Vitro and in Vivo

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma.

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Mycobacterium Tuberculosis infection and Tissue Factor Expression in Macrophages

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Mice That Lack RhoA In Their Platelets Have Normal Actin Dynamics, but Have Macrothrombocytopenia

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Bryostatin Enhances the Cytotoxic Effects of Anti-CD22 Immunotoxins in CLL by Two Distinct Mechanisms: Implications for a Sequential Therapy.

Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only